Objectives. HCQ has been described as having a beneficial effect in patients with APS but its mechanism of action is unclear. We hypothesized that HCQ may have effects on subnormal angiogenesis, inflammation and haemostatic biomarkers seen in APS. The aim of our study was to assess laboratory markers [annexin A5 (AnxA5) anticoagulant activity, tissue factor (TF) levels, thromboelastography (TEG), CRP, Bb, C3a and VEGF] in HCQ-naïve patients with aPL at baseline and after commencing HCQ.
Introduction
HCQ is an immunomodulator used in SLE [1] , improving symptoms and survival and reducing thrombotic events [1] . APS is the association of venous, microvascular and/or arterial thrombosis and/or pregnancy-associated morbidity with persistent aPL [2] . Clinical studies suggest a beneficial effect of the use of HCQ in APS in thrombotic and obstetric APS [36] . However, the mechanism of action of HCQ in improving APS outcome is unexplained [1] .
Our knowledge on the effects of HCQ in patients with aPL stem mainly from in vitro and animal models, for human data remain scarce. Animal models show that HCQ has the ability to reverse aPL-induced thrombotic properties [7] . However, the pathogenic mechanisms of how aPL causes morbidity remain unclear, although there is evidence that complement, haemostatic, inflammatory and angiogenic pathways are involved [8] .
In a mouse model, HCQ prevented aPL-induced fetal loss by inhibiting complement activity [9] . HCQ also restores the aPL-induced disruption of the physiological anticoagulant AnxA5 in vitro [10] , and it directly affects the formation of aPL immune complexes [11] , reduces the binding of aPL to syncytiotrophoblasts and restores AnxA5 expression [12] .
Tissue factor (TF), the key initiator of coagulation and a mediator of angiogenesis, has been proposed to play a role in the pathogenesis of APS [8] . aPL-induced up-regulation of TF has been shown in monocytes, neutrophils and on endothelial cells in vitro [8] . We and others have previously shown elevated levels of soluble VEGF [13] and VEGF expressed on monocytes [14] in patients with primary APS. Angiogenic markers have been proposed as biomarkers for adverse pregnancy outcomes in healthy women and in women with aPL [15] .
To the best of our knowledge the effects of HCQ on angiogenic, haemostatic and inflammatory biomarkers in patients with APS have not been studied. We hypothesize that HCQ affects these biomarkers. We used thromboelastography (TEG) to provide assessment of global haemostasis.
Methods

Study design and patients
This was an observational prospective study where patients with aPL and APS who were due to start HCQ had blood samples taken before and 3 months after starting 200 mg HCQ daily. Patients with aPL or APS who were being considered for treatment with HCQ as part of routine management were approached and recruited from our APS clinic from March 2010 until March 2011. All patients gave their consent to participate. Ethical approval was obtained from the South London ethics committee at Guy's & St Thomas' Trust. Patient's demographic details (date of birth, sex, ethnicity, APS related complications, SLE related complications, risk factors for thrombosis and current medications) were recorded. The study excluded patients <18 years, pregnancy, thrombotic event in the previous 3 months, patients unwilling to participate or unable to give fully informed consent and patients with any contraindication to HCQ. Blood specimens were collected from patients with APS before and 12 weeks after starting 200 mg HCQ daily.
Bloods sample collection and processing Blood was drawn using flawless venipuncture into Vacutainer tubes prefilled with potassium EDTA, 0.105 M trisodium citrate and processed within 3 h of collection. Samples were double centrifuged at 3000 g for 15 min at room temperature. Serum and plasma were aliquoted into Eppendorf tubes and stored at À80 C until testing. Samples were analysed for aPL (LA, aCL and anti-domain1 b2 glycoprotein1 IgG activity), TEG, CRP, soluble TF, VEGF, anti-domain 1 IgG activity and AnxA5 activity. aPL determination and solid phase assays Patients with APS or isolated aPL had already demonstrated positive testing for aPL (LA, IgG/IgM aCL or IgG/IgM antib2-glycoprotein I antibodies) on two occasions >12 weeks apart [2] .aPL (isotypes IgG and IgM) were quantified by indirect ELISA using AEUSKULISA Cardiolipin-GM reagents (Grifols UK, Cambridge, UK). Anti-b2-glycoprotein I antibodies (isotypes IgG and IgM) were quantified by indirect ELISA using QUANTA Lite reagents (Inova Diagnostics Inc., San Diego, CA, USA). Positive cut-off values for both were determined according to Sydney Criteria (>99th percentile).
LA detection
LA was determined by dilute Russell viper venom time and dilute activated partial thromboplastin time (APTT) in compliance with published guidelines [15] . Dilute Russell's viper venom time was performed with Life Diagnostics LA Screen and LA Confirm reagents (Life Therapeutics, Clarkston, GA, USA). Dilute APTT was performed using PTTLA (Diagnostica Stago, Asnié res, France) in the screen with a platelet neutralization procedure employing Biodata Platelet Extract Reagent (Alpha Laboratories, Eastleigh, UK) in the phospholipid-dependence confirmatory test. Patients on oral anticoagulation received testing with the Taipan snake venom time employing Diagen Taipan venom (Diagnostic Reagents, Thame, UK) and the ecarin time confirmatory test using Echis carinatus venom (Diagnostic Reagents). All elevated screens received the confirmatory test plus a screen and confirmatory test on 1:1 mixing studies with normal plasma. Technoclone lyophilized platelet poor plasma (Pathway Diagnostics Ltd, Dorking, UK) was used as the normal plasma throughout.
ELISA
All ELISAs were performed according to the manufacturer's protocol. Soluble TF (Invitech Ltd, Huntingdon, UK) had intra-assay and interassay CV of 6.0 and 5.0%, respectively. Complement fragment Bb and C3a-des-Arg ELISA assays (Microvue Bb Plus and C3a EIA kits, Quidel, Pathway diagnostics ltd., Dorking, UK) were used on EDTA plasma samples in two batches. VEGF-A (R&D systems, Abingdon, UK) had intra-assay and interassay CV of 4.8 and 7.4%, respectively.
AnnexinA5 activity analysis and CRP analysis AnnexinA5 (AnxA5) anticoagulant activity of patient plasma was assessed as previously described [16] . The anticoagulant activity of AnxA5 was expressed as the AnxA5 anticoagulant ratio: (coagulation time in the presence of AnxA5/coagulation time in the absence of AnxA5) Â 100%. CRP was measured using the Roche Cobas modular analyser (Roche Diagnostics Ltd., West Sussex, U.K.) according to the manufacturer's protocol.
TEG analysis
Fresh whole blood was drawn by flawless venepuncture into Vacutainers containing 0.105 M citrate in a ratio of 9:1 and stored at room temperature for up to 3 h prior to analysis. Five hundred microlitres of whole blood was activated with 12.5 ml of kaolin, 340 ml of this was placed in a TEG cup and thromboelastography was performed by the same trained individual according to the manufacturer's protocol. Reference ranges for TEG are as follows: 
Statistical analysis
There were no previous data in this area, so we were unable to do a power calculation to work out study size for this pilot study. Statistical analysis was performed using SPSS Statistics Version 22 (IBM Corp., Armonk, NY, USA). Student's t test was performed for continuous normally distributed data and Wilcoxon's rank test was performed for non-normally distributed data. A value of P = 0.05 was considered as significant.
Results
Twenty-two patients (20 females and 2 males) with a median age of 47 (range 1869) years were studied (Table 1) . Fourteen patients were treated with warfarin. Two women had previous recurrent miscarriages, one patient had a history of severe pre-eclampsia, one child was growth restricted and there were three stillbirths. Soluble TF levels were significantly reduced 3 months after HCQ commencement 
Discussion
Our results showed that HCQ use was associated with a significant reduction in soluble TF levels in APS patients 12 weeks after commencement of HCQ, but there were no statistically significant changes in other biomarkers. There is substantial evidence of a role for TF in APS. aPL can stimulate the up-regulation of TF in monocytes, neutrophils and endothelium [8] . Serum, plasma, purified total IgG and antiB2GPI from APS patients increases TF expression and the pro-coagulant activity on monocytes in vitro [8] . Lopez-Pedrera et al. [17] showed that aCL IgG stimulated TF expression on circulating monocytes. Neutrophils express TF through aPL-induced complement activation [18] . Possibly reduction of soluble TF levels may reflect a mechanism contributing to HCQ's antithrombotic effect in aPL/APS. Further studies on HCQ's effect on TF activity are needed.
We previously found significantly elevated levels of VEGF in patients with primary APS [13, 14] , and our current study again confirms this; but we had also previously found elevated C3a-des-Arg and Bb levels in a cohort of 186 APS patients compared with healthy controls [19] and were surprised this was not present in our current study. Recently, Bertolaccini et al. [9] reported HCQ-induced complement inhibition in APS serum, specifically measuring the common pathway complement activation product C5a-des-Arg after receiving 6.5 mg/kg HCQ for 6 months (which equals >400 mg in a patient weighing 75 kg). There are a number of possibilities for the differences we saw: perhaps the shorter duration and lower dose of HCQ in our studies compared with Bertolaccini's patients might be important, or the fact that we are looking at different complement pathways. AnxA5 activity was not significantly altered in our patients by HCQ. Previous data by Rand et al. showed that in vitro HCQ restores the AnxA5 anticoagulant shields on the surface of umbilical cord and trophoblast cell lines [10] , and that plasma AnxA5 anticoagulant activity from 10 patients with aPL was significantly increased in the presence of exogenously added HCQ [10] . Our study showed no significant change in anti-domain 1 activity, suggesting that HCQ does not alter antibody activity. Apart from a prolonged mean TEG:R reflecting warfarin treatment, TEG parameters were within reference ranges, which supports the two-hit hypothesis: that aPL do not cause a hypercoagulable state per se, but that a second hit is required to result in clinical manifestations [8] .
Drawbacks of our study relate to its being a pilot study: it may have been insufficiently powered to show HCQ's effect on the biomarkers we studied and our finding may therefore be by chance. Secondly, in our study we measured soluble TF antigen and we acknowledge that other studies have highlighted the associated challenges in using soluble TF antigen as a reflection of TF activity [20, 21] . Future studies assessing the effect of HCQ on TF activity would provide valuable knowledge.
Moreover, the patient cohort consisted mainly of women and we did not assess patient compliance in taking HCQ. In future studies we plan to assess HCQ blood levels. The plasma equilibrium of HCQ is said to be established after 4 weeks in other disease [22] , but studies of pharmacokinetics of HCQ in APS have not been published, so our assessment of patients at 12 weeks may have been too soon. Fourteen patients were receiving vitamin K antagonists but no pharmaceutical interactions of HCQ and vitamin K antagonists or aspirin have been reported. Indeed none of our patients were receiving heparins, which in murine models were shown to affect aPL-mediated complement activation [23] . Lastly, there are no high quality studies but only retrospective case series and one prospective nonrandomized trial on 40 patients with APS reporting that HCQ is beneficial in APS [3, 6, 5] . The first randomized controlled trial assessing the effect of HCQ on pregnancy outcome in pregnant women with aPL is due to start, and further studies on HCQ's effect on endothelial activation in APS patients are underway.
Summary
We assessed the effect of HCQ on haemostasis, complement, inflammation and angiogenesis in HCQ-naïve patients and found a significant reduction in soluble TF levels in aPL positive patients after the use of HCQ. No statistically significant change was observed in AnxA5 activity, anti-domain 1 activity, TEG, CRP, complement spilt products Bb and C3a-des-Arg, and VEGF. Further studies of a larger patient cohort and with a larger dose of HCQ may be useful to confirm or refute the observed reduction in soluble TF levels in patients with aPL/APS.
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